One (1) Cobas Liat Assays Analyzer, Associated PCR Kits, and Comprehensive Maintenance

SOL #: PANDHA26P0000034421Special NoticeSole Source

Overview

Buyer

DEPT OF DEFENSE
Defense Health Agency (Dha)
DEFENSE HEALTH AGENCY
FREDERICK, MD, 21702, United States

Place of Performance

Charleston AFB, SC

NAICS

Medical Laboratories (621511)

PSC

Reference Laboratory Testing (Q301)

Set Aside

No set aside specified

Timeline

1
Posted
Jun 1, 2026
2
Action Date
Jun 19, 2026, 4:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Health Agency (DHA), specifically the Healthcare Contracting Division, Southeast (DHACA-HCD-SE), has issued a Notice of Intent to Sole Source a firm-fixed-price contract to Roche Diagnostics. This action is for the provision of one (1) Cobas Liat Assays Analyzer, associated PCR kits, and comprehensive maintenance services for the 20th Medical Group at Shaw Air Force Base, SC. This is not a request for competitive proposals, but interested parties may submit capability statements by June 19, 2026, 12:00 PM EST.

Scope of Work

The requirement includes a molecular real-time polymerase chain reaction service, encompassing:

  • One (1) new Cobas Liat Assays Analyzer.
  • All necessary PCR test kits (including SARS-CoV-2, Influenza A/B, RSV, and Strep A assays).
  • Comprehensive maintenance support for both new and existing units.
  • Provision of qualified personnel, equipment, supplies, and services.
  • The system must be CLIA waived for Influenza A/B, RSV, SARS-CoV-2, and Streptococcus A assays.

Contract & Timeline

  • Contract Type: Firm-fixed-price, sole-source.
  • Authority: FAR 6.302-1, "Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements."
  • Period of Performance: Base Delivery Period from September 1, 2026, to August 31, 2027, with four (4) one-year option periods, extending through August 31, 2031.
  • Estimated Volume: Approximately 3,300 – 3,800 tests per year.
  • NAICS Code: 621511 (Medical Laboratories), Small Business Size Standard: $41.5 Million.
  • Capability Statement Due: June 19, 2026, 12:00 PM EST.
  • Published Date: June 1, 2026.

Evaluation

This is not a competitive solicitation. Capability statements are for informational purposes only to determine if a competitive procurement is warranted. The government intends to award to Roche Diagnostics due to proprietary equipment and unique capabilities.

Additional Notes

  • The Cobas Liat system offers a rapid Turnaround Time (TAT) of 20 minutes from a single nasal sample.
  • The multiplex assay can test for SARS-CoV-2, Influenza A/B, and RSV simultaneously.
  • There are no set-aside restrictions for this requirement.

People

Points of Contact

Lenore Y. PasedaPRIMARY
Rebecca BrashearsSECONDARY

Files

Files

Download

Versions

Version 1Viewing
Special Notice
Posted: Jun 1, 2026
One (1) Cobas Liat Assays Analyzer, Associated PCR Kits, and Comprehensive Maintenance | GovScope